Aktie im Blick: Anleger misstrauen den Zukunftsplänen von Novo Nordisk

Last week, the focus of discussion among investors was not a single European stock, but Novo Nordisk. This became apparent on various international digital stock forums. The catalyst was the highly anticipated capital market day for the Danish pharmaceutical company in London last Monday. At this event, Novo Nordisk announced plans to bring more than five blockbuster medications to market by 2030.

These are particularly revenue-generating drugs. By 2035, the company expects such products to generate over €20 billion in revenue. Significant attention was given to research data on Cagri-Sema, a new weight loss drug. The weight loss from this medication is expected to be greater than that achieved with existing drugs. An FDA approval decision is expected in the fourth quarter of this year.

Additionally, Novo Nordisk aims to tap into growth areas such as cardiovascular diseases, liver diseases, and blood disorders. However, these are merely ambitions, not concrete financial forecasts. Consequently, the stock lost about ten percent of its value last week. Investors were hoping for more details and revenue projections instead of ambitious statements reaching into the distant future.

Some analyst houses, including Jefferies and Deutsche Bank, subsequently lowered their target prices.